Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211900 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Manufacturing Lot of StaphVAX
A Phase 3 study, sponsored by Nabi Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 65
- Enrollment target
NCT00211900: Completed Phase 3 study, sponsored by Nabi Biopharmaceuticals.
NCT00211900 is a Phase 3 study that has completed, run by Nabi Biopharmaceuticals. The registered enrollment target is 65 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00211900, a Phase 3 study, has completed, sponsored by Nabi Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 65 participants
- Enrollment target
Study Summary
This study answers a U.S. Food and Drug Administration requirement for evaluation in people of a manufacturing lot of vaccine. Subjects receive one dose of one lot of vaccine. The antibodies in the blood measure the immunogenicity of the vaccine, and typical vaccine safety information is also collected.
Interventions
- BIOLOGICAL S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
What the finished NCT00211900 record still lists
NCT00211900 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine is the first listed.
NCT00211900 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00211900 about?
NCT00211900 is a clinical study titled "Evaluation of Manufacturing Lot of StaphVAX". This study answers a U.S. Food and Drug Administration requirement for evaluation in people of a manufacturing lot of vaccine. Subjects receive one dose of one lot of vaccine. The antibodies in the blood measure the immunogenicity of the vaccine, and typical vaccine safety information is also collec...
What is the current status of trial NCT00211900?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 65 participants. The study started on 2005-03. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00211900?
The interventions under investigation include: S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00211900?
This trial is sponsored by Nabi Biopharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00211900's enrollment target sits among peer trials
65 1797th of 2000 higher than 202 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia